Cheng, Hui <br/><br/>
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.  [electronic resource] 

 -  Circulation research  Dec 2011 
 - 1401-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1524-4571 
<br/><br/><label>Standard No.: </label>10.1161/CIRCRESAHA.111.255695  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Animals, Genetically Modified<br/>Apoptosis--drug effects<br/>Benzenesulfonates--pharmacology<br/>Cardiotoxins--pharmacology<br/>Cell Survival--drug effects<br/>Cells, Cultured<br/>Extracellular Signal-Regulated MAP Kinases--antagonists & inhibitors<br/>Female<br/>Gefitinib<br/>Indoles--pharmacology<br/>Male<br/>Models, Animal<br/>Myocytes, Cardiac--cytology<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-raf--antagonists & inhibitors<br/>Pyridines--pharmacology<br/>Pyrroles--pharmacology<br/>Quinazolines--pharmacology<br/>Rats<br/>Rats, Sprague-Dawley<br/>Signal Transduction--drug effects<br/>Sorafenib<br/>Sunitinib<br/>Zebrafish